Medetomidine: The 2026 Adulterant to Watch
A veterinary sedative called medetomidine is spreading through North America's opioid supply, causing overdose spikes that naloxone cannot fully reverse.
The Sedative Filling Xylazine's Gap
Medetomidine is a veterinary sedative, in the same family as xylazine but different enough that standard tests miss it. Through 2026, it has become the standout adulterant in North America's opioid supply.
It is not an opioid, so naloxone does not reverse it. That is what makes medetomidine overdose spikes so hard to treat.
The Spikes Are Real
In June 2026, the Canadian city of Moncton saw an overdose surge that officials blamed on drugs tainted with a veterinary tranquilizer. The Globe and Mail and CBC both covered it, with one health official saying they had never seen a spike like it.
A similar surge hit Penticton, British Columbia, in June 2026, as CBC reported.
In the United States, the Star Tribune reported in July 2026 that medetomidine was creeping into Minnesota's fentanyl supply. Baltimore City issued its own ongoing threat alert in June 2026.
States Are Moving to Schedule It
Pennsylvania's House moved in July 2026 to formally schedule medetomidine, the Pittsburgh Post-Gazette reported. Scheduling is a sign of how fast the drug has gone from obscure veterinary product to public health concern.
What This Means for Testing
Fentanyl strips do not detect medetomidine. Xylazine strips detect xylazine, not medetomidine. You need a dedicated medetomidine strip, and you need to run the whole stack.
See our medetomidine test strips guide for how to test.
Disclosure: This article is for education only. Testing reduces risk; it never eliminates it.
Ready to Test Safely?
All reagents, test strips, and testing accessories mentioned in this guide are available in our catalog — shipped discreetly worldwide.